Evidence map›Paper›PMID 41889821›Full record

ArticlebioRxiv : the preprint server for biology2026

Knockdown of the long isoform of the prolactin receptor selectively targets pathogenic immune cells in systemic lupus erythematosus and averts glomerular pathology.

Kory Hamane, Zunsong Hu, Joao Rodrigues Lima-Junior, Adeleh Taghi Khani, Anil Kumar, Ashly Sanchez Ortiz, Xinying Guo, Da Hae Jung, Hanjun Qin, Shu Tao and 9 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kory HamaneDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Zunsong HuDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Joao Rodrigues Lima-JuniorDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Adeleh Taghi KhaniDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Anil KumarDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Ashly Sanchez OrtizDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Xinying GuoDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Da Hae JungDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Hanjun QinDepartment of Molecular and Cellular Biology, City of Hope National Medical Center, Duarte, CA 91010, USA.
Shu TaoDepartment of Molecular and Cellular Biology, City of Hope National Medical Center, Duarte, CA 91010, USA.
Ignacio SanzDepartment of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, 30322, USA.
Eric MeffreDivision of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Katherine MarzanDivision of Rheumatology, Children's Hospital Los Angeles, CA 90027, USA.
Jean L KoffDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.
Mary Y LorensonDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, CA 92521, USA.
Zhaohui GuDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Xiwei WuDepartment of Molecular and Cellular Biology, City of Hope National Medical Center, Duarte, CA 91010, USA.
Ameae M WalkerDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, CA 92521, USA.
Srividya SwaminathanDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignanciesR37CA276517 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Srividya Swaminathan · 2023 to 2026
$1.7M
Concurrent eradication of pathogenic plasma cells and their precursors in systemic lupus erythematosusR21AR084116 · NIAMS · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI SWAMINATHAN, SRIVIDYA · 2024 to 2024
$415k
NCI NIH HHS P30 CA033572NCI NIH HHS R37 CA276517NIAMS NIH HHS R21 AR084116
6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by chronic inflammation in multiple organ systems. While a clinical association between elevated levels of the hormone/cytokine, prolactin (PRL), and exacerbation of SLE has been recognized for some time, little is known about the mechanisms through which PRL affects the course of this disease. Here, we show that immune cells in SLE have aberrant splicing of the prolactin receptor (PRLR) such that the ratio of the long to short splice variants is increased. To determine whether the change in PRLR isoform expression was causal in this disease, we used a splice-modulating oligomer (SMO) that knocked down expression of the long splice variant (LFPRLR). Using patient samples

Identifiers

PMID41889821
PMCPMC13015481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.